Friday, July 10, 2026

pharma · Glaucoma · Macular Edema

Allergan Pharmaceuticals International

Allergan Pharmaceuticals International is a pharma organization headquartered in Dublin, IE. Primary therapeutic focus areas include Glaucoma, Macular Edema, Macular Degeneration, Dry Eye Syndromes, Choroid Neovasculariz

Dublin, IE HQ
EMA registrant Type
Company details
Clinical program

Gatifloxacin 0.3% ophthalmic solution

Phase 2 · small molecule · Acute Bacterial Corneal Ulcers

Gatifloxacin 0.3% ophthalmic solution for Acute Bacterial Corneal Ulcers is a Phase 2 program (small_molecule) at Allergan Pharmaceuticals International Limited with 1 ClinicalTrials.gov record(s).

Internal code 198782-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Allergan Pharmaceuticals International Limited
Phase
Phase 2
Modality
small_molecule
Indication
Acute Bacterial Corneal Ulcers
Status
completed
Trials
1